PLYMOUTH MEETING, Pa.,
Dec. 15, 2014 /PRNewswire/
-- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today
it has been added to the NASDAQ Biotechnology Index (NBI). The
addition to the NASDAQ Biotechnology Index will become effective
upon market open on December 22,
2014.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of NASDAQ-listed securities that are
classified as either biotechnology or pharmaceutical according to
the Industry Classification Benchmark. The NASDAQ Biotechnology
Index is re-ranked annually in December. The NASDAQ Biotechnology
Index forms the basis for the iShares NASDAQ Biotechnology Index
Fund (IBB) which seeks investment results that correspond generally
to the price and yield performance, before fees and expenses, of
the NASDAQ Biotechnology Index. In addition, options based on the
iShares NASDAQ Biotechnology Index Fund trade on various exchanges.
For more information about the NASDAQ Biotechnology Index
visit:
https://indexes.nasdaqomx.com/Index/Overview/NBI.
Dr. J. Joseph Kim, President
& CEO of Inovio, said, "This addition is another milestone for
Inovio as we advance our DNA immunotherapies and
vaccines. We're pleased to meet the criteria for inclusion
into the most influential biotechnology index."
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and
infectious diseases. Our immunotherapies uniquely activate
best-in-class immune responses to prevent and treat disease, and
have shown clinically significant efficacy with a favorable safety
profile. With an expanding portfolio of immune therapies, the
company is advancing a growing preclinical and clinical stage
product pipeline. Partners and collaborators include Roche,
MedImmune, University of Pennsylvania,
DARPA, Drexel University, NIH, HIV
Vaccines Trial Network, National Cancer Institute, U.S. Military
HIV Research Program, and University of
Manitoba. For more information, visit www.inovio.com.
CONTACTS:
Investors: Bernie Hertel, Inovio
Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio
Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines, our expectations regarding our research and development
programs and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, including safety and efficacy for VGX-3100, that
pre-clinical studies and clinical trials may not commence or be
completed in the time periods anticipated, that results from one
study may not necessarily be reflected or supported by the results
of other similar studies and that results from an animal study may
not be indicative of results achievable in human studies), the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon® active immune
therapy and vaccine products, our ability to advance our portfolio
of immune-oncology products independently, including INO-5150, and
to commence a phase I clinical trial for INO-5150 in the first half
of 2015, the adequacy of our capital resources, the availability or
potential availability of alternative therapies or treatments for
the conditions targeted by the company or its collaborators,
including alternatives that may be more efficacious or
cost-effective than any therapy or treatment that the company and
its collaborators hope to develop, our ability to enter into
partnerships in conjunction with our research and development
programs, evaluation of potential opportunities, issues involving
product liability, issues involving patents and whether they or
licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2013, our Form 10-Q for the quarter
ended September 30, 2014, and other
regulatory filings from time to time. There can be no assurance
that any product in Inovio's pipeline will be successfully
developed or manufactured, that final results of clinical studies
will be supportive of regulatory approvals required to market
licensed products, or that any of the forward-looking information
provided herein will be proven accurate.
Logo -
http://photos.prnewswire.com/prnh/20131118/LA18202LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/inovio-pharmaceuticals-added-to-nasdaq-biotechnology-index-300009308.html
SOURCE Inovio Pharmaceuticals, Inc.